Cepheid (CPHD) Bacterial Infection Test Gets FDA Clereance

Cepheid Inc. (CPHD) shares gained as much as 9 percent to $17.93, the most intraday since May 10, after the maker of a rapid test for drug-resistant staph infections said the U.S. Food and Drug Administration [FDA] approved its Xpert SA Nasal Complete, a diagnostic molecular test to detect and differentiate two infection-causing bacteria, Staphylococcus aureus [SA] and Methicillin-resistant Staphylococcus aureus [MRSA] in less than an hour.

According to Cepheid, the product is the first molecular test designed for the simultaneous detection of both of SA & MRSA colonization.

“Up to 93 percent of hospital-acquired SA infections are caused by a patient’s own colonized flora, making SA nasal carriers nearly 9 times more likely to develop surgical site infections than non-carriers,” Cepheid said in a prepared statement.

CEO John Bishop said the availability of an accurate and rapid SA/MRSA test “should help to improve clinicians’ efforts to prevent and control Healthcare Associated Infections identified with colonized patients. HAIs in general are responsible for nearly $30 billion in associated healthcare expenses in the US each year.”

CPHD is up 12 cents, or 0.73%, to $16.61 at 12:10PM EDT in Nasdaq composite trading.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.